Janssen nears goal of moving patients to new version of Genmab's Darzalex

80% of sales of cancer treatment, daratumumab, in Europe is now comprised of Darzalex Faspro, administered subcutaneously rather than via infusion. The proportion is even larger in the US.

Photo: George Frey/Reuters/Ritzau Scanpix

Janssen is close to achieving its aim of converting sales of bone marrow cancer drug Darzalex (daratumumab) into a newer version called Darzalex Faspro, administered subcutaneously rather than via infusion, reports sector media Fierce Pharma based on information from the Danish biotech firm’s investor meeting following the release of the second-quarter report. The interim statement shows that 85% of the treatment’s US sales has now moved from Darzalex to Darzalex Faspro, while the percentage for the EU is 80%.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs